IP Library › Patent Application 15945420
Patent Application
App. No. 15/945,420

TRANSDERMAL SYSTEMS CONTAINING MULTILAYER ADHESIVE MATRICES TO MODIFY DRUG DELIVERY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/945,420
Abstract

A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix. The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.

Claims (23)

1 - 47 . (canceled)

48 . A transdermal drug-containing dosage unit comprising:

a. a backing layer substantially impervious to the drug to be delivered transdermally;

b. a polymeric adhesive system comprising:

i. a drug consisting of estradiol in an amount from 1.25% to about 4.0% w/w,

ii. an acrylic adhesive,

iii. a silicon adhesive,

iv. povidone, and

v. a solvent, wherein the polymeric adhesive system has a thickness of at least about 100 gsm; and

c. a release liner in contact with the polymeric adhesive system.

49 . The transdermal drug-containing dosage unit of claim 48 , wherein the estradiol is estradiol hemihydrate.

50 . The transdermal drug-containing dosage unit of claim 48 , wherein the polymeric adhesive system has a thickness of about 125 gsm.

51 . The transdermal drug-containing dosage unit of claim 48 , wherein the polymeric adhesive system has a thickness of about 150 gsm.

52 . The transdermal drug-containing dosage unit of claim 48 , wherein a thickness of the backing layer and a thickness of the polymeric adhesive system can be modified to change a drug delivery rate of the drug-containing dosage unit.

53 . A transdermal drug-containing dosage unit comprising:

a. a backing layer substantially impervious to the drug to be delivered transdermally;

b. a polymeric adhesive system comprising:

i. a drug consisting of estradiol in an amount from about 0.1% to about 4.0% w/w,

ii. an acrylic adhesive,

iii. a silicon adhesive,

iv. povidone, and

v. a solvent, wherein the polymeric adhesive system has a thickness of between about 5 and 150 gsm; and

c. a release liner in contact with the polymeric adhesive system.